New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

West Pharmaceutical Services, Inc.

WST

Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+57.3%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

390.56 6.13 −1.55%

After hours trading: 390.30, down 0.07%, last trade 5:54pm Eastern.

Market cap
$27.6B
P/E
43.5×
Fwd P/E FY26e
44.6×
Dividend yield
0.24%
F-score
8/9
ROIC
18.0%
Net debt / EBITDA
−0.8×
Payout ratio
0.1×

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

Of every $100 of revenue, $24.47 was left as profit. Gross margin has risen two quarters running, from 35.1% to 39.7%. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue874.5100.0%
Cost of revenue−527.1−60.3%
Gross profit347.439.7%
Research & development−18.3−2.1%
Selling, general & admin−112.9−12.9%
Other operating costs+51.25.9%
Operating income267.430.6%
Income tax−58.0−6.6%
Other items+4.30.5%
Net income214.024.5%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$805M$845M$872M$874M
Operating income$157M$177M$179M$267M
Net income$132M$139M$154M$214M
Net margin (right axis)16.4%16.4%17.7%24.5%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
874.50 872.30 844.90 805.00

+8 more quarters

Revenue Growth
8.69% 13.80% 21.05% 7.51%
Cost of Revenue
527.10 543.10 548.50 501.10
Gross Profit
347.40 329.20 296.40 303.90
R&D Expenses
18.30 19.70 15.80 21.80
SG&A Expenses
112.90 117.60 99.50 107.00
Operating Income
267.40 179.10 177.10 156.60
Non-operating Interest Expenses
3.80 2.60 1.90 (0.20)
Non-operating Income/Expense
0.30 1.00 3.00 4.90
EBT
267.70 180.10 180.10 161.50
Income Tax Provision
58.00 32.20 44.70 33.30
Income after Tax
209.70 147.90 135.40 128.20
Share of Subsidiary Earnings
4.30 6.10 3.40 3.90
Net Income Common
214.00 154.00 138.80 132.10
EPS (Basic)
3.04 2.17 1.93 1.83
EPS (Diluted)
3.02 2.15 1.92 1.82
Shares (Basic, Weighted)
70.40 70.80 72.00 72.30
Shares (Diluted, Weighted)
70.80 71.30 72.40 72.70
Gross Margin
39.73% 37.74% 35.08% 37.75%
EBIT Margin
30.58% 20.53% 20.96% 19.45%
EBT margin
30.61% 20.65% 21.32% 20.06%
Net Profit Margin
24.47% 17.65% 16.43% 16.41%
EBITDA
313.30 225.30 222.30 203.60
EBIT
267.40 179.10 177.10 156.60
Income from Continuous Operations
214.00 154.00 138.80 132.10
Consolidated Net Income/Loss
214.00 154.00 138.80 132.10
EPS (Basic, from Continuous Ops)
3.04 2.18 1.93 1.83
EPS (Diluted, from Cont. Ops)
3.02 2.16 1.92 1.81
EPS (Basic, Consolidated)
3.04 2.18 1.93 1.83
EPS (Diluted, Consolidated)
3.02 2.16 1.92 1.81
Shares (Diluted, Average)
70.80 71.30 72.40 72.70
EBITDA Margin
35.83% 25.83% 26.31% 25.29%
Operating Cash Flow Margin
21.67% 14.22% 10.64% 31.19%

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026